Literature DB >> 21835286

Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy.

Sabe De1, Allen G Borowski, Heng Wang, Leah Nye, Baozhong Xin, James D Thomas, W H Wilson Tang.   

Abstract

BACKGROUND: Early diastolic myocardial tissue Doppler velocities have reported to be reduced in mutation-positive patients with hypertrophic cardiomyopathy (HCM) in some studies even in the absence of left ventricular hypertrophy (LVH). Strain is a sensitive tool in detecting early systolic abnormalities in patients with HCM. Our goal is to examine novel echocardiographic characteristics of phenotype-negative carriers for a known sarcomeric gene mutation for HCM.
METHODS: We evaluated 41 consecutive subjects with a known myosin-binding protein C3 (MYBPC3) mutation (c.3330+2T>G). Subjects who were mutation positive without LVH (G+/LVH-, n = 35) were compared with healthy controls (n = 30) regarding tissue Doppler and segmental longitudinal strain measures.
RESULTS: The G+/LVH- group was similar to the healthy controls with respect to chamber size, left ventricular mass index, and most diastolic filling parameters, including tissue Doppler-derived early diastolic annular velocities. Global longitudinal strain was similar for both groups (20.3 ± 2.1 vs 19.8 ± 1.8, P = .36), although regional segment analysis showed a notable reduction in the basal septum (16.8 ± 3.1 vs 19.0 ± 4.0%, P = .02) and increase in the basal posterior (22.5 ± 5.2 vs 17.9 ± 5.2, P = .001) as well as mid posterior (21.8 ± 4.7 vs 18.2 ± 3.0, P = .001) walls.
CONCLUSIONS: In our cohort of phenotype-negative carriers of a specific MYBPC3 mutation, there were minimal differences in conventional 2-dimensional, Doppler, and speckle-tracking-derived parameters of systolic and diastolic function compared with that of healthy subjects. The presence of regional alterations in strain indicative of the presence of underlying subclinical disease requires further validation.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21835286      PMCID: PMC3155874          DOI: 10.1016/j.ahj.2011.05.018

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  18 in total

1.  Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy.

Authors:  A J Marian
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

Review 2.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines.

Authors:  Barry J Maron; William J McKenna; Gordon K Danielson; Lukas J Kappenberger; Horst J Kuhn; Christine E Seidman; Pravin M Shah; William H Spencer; Paolo Spirito; Folkert J Ten Cate; E Douglas Wigle
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

3.  Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function.

Authors:  Marina Leitman; Peter Lysyansky; Stanislav Sidenko; Vladimir Shir; Eli Peleg; Michal Binenbaum; Edo Kaluski; Ricardo Krakover; Zvi Vered
Journal:  J Am Soc Echocardiogr       Date:  2004-10       Impact factor: 5.251

4.  Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy.

Authors:  S F Nagueh; L L Bachinski; D Meyer; R Hill; W A Zoghbi; J W Tam; M A Quiñones; R Roberts; A J Marian
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

5.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

Review 6.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography.

Authors:  Sherif F Nagueh; Christopher P Appleton; Thierry C Gillebert; Paolo N Marino; Jae K Oh; Otto A Smiseth; Alan D Waggoner; Frank A Flachskampf; Patricia A Pellikka; Arturo Evangelista
Journal:  J Am Soc Echocardiogr       Date:  2009-02       Impact factor: 5.251

7.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy.

Authors:  H Niimura; L L Bachinski; S Sangwatanaroj; H Watkins; A E Chudley; W McKenna; A Kristinsson; R Roberts; M Sole; B J Maron; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

8.  Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.

Authors:  Michelle Michels; Osama I I Soliman; Marcel J Kofflard; Yvonne M Hoedemaekers; Dennis Dooijes; Danielle Majoor-Krakauer; Folkert J ten Cate
Journal:  JACC Cardiovasc Imaging       Date:  2009-01

9.  Familial screening and genetic counselling in hypertrophic cardiomyopathy: the Rotterdam experience.

Authors:  M Michels; Y M Hoedemaekers; M J Kofflard; I Frohn-Mulder; D Dooijes; D Majoor-Krakauer; F J Ten Cate
Journal:  Neth Heart J       Date:  2007-05       Impact factor: 2.380

10.  Homozygosity for a novel splice site mutation in the cardiac myosin-binding protein C gene causes severe neonatal hypertrophic cardiomyopathy.

Authors:  Baozhong Xin; Erik Puffenberger; John Tumbush; J R Bockoven; Heng Wang
Journal:  Am J Med Genet A       Date:  2007-11-15       Impact factor: 2.802

View more
  9 in total

1.  Could two-dimensional radial strain be considered as a novel tool to identify pre-clinical hypertrophic cardiomyopathy mutation carriers?

Authors:  Gloria Maria Santambrogio; Alessandro Maloberti; Paola Vallerio; Angelica Peritore; Francesca Spanò; Lucia Occhi; Francesco Musca; Oriana Belli; Benedetta De Chiara; Francesca Casadei; Rita Facchetti; Fabio Turazza; Emanuela Manfredini; Cristina Giannattasio; Antonella Moreo
Journal:  Int J Cardiovasc Imaging       Date:  2019-07-18       Impact factor: 2.357

2.  Three-dimensional speckle tracking echocardiography for the preclinical diagnosis of hypertrophic cardiomyopathy.

Authors:  Mohamed F A Aly; Wessel P Brouwer; Sebastiaan A Kleijn; Albert C van Rossum; Otto Kamp
Journal:  Int J Cardiovasc Imaging       Date:  2014-01-30       Impact factor: 2.357

3.  Morphological and functional abnormalities pattern in hypertrophy-free HCM mutation carriers detected with echocardiography.

Authors:  Jérôme Peyrou; Patricia Réant; Amélie Reynaud; Claire Cornolle; Marina Dijos; Caroline Rooryck-Thambo; Mathieu Landelle; Michel Montaudon; François Laurent; Raymond Roudaut; Stéphane Lafitte
Journal:  Int J Cardiovasc Imaging       Date:  2016-06-20       Impact factor: 2.357

4.  Abnormal Mitral Valve Dimensions in Pediatric Patients with Hypertrophic Cardiomyopathy.

Authors:  Daryl Schantz; Lee Benson; Jonathan Windram; Derek Wong; Andreea Dragulescu; Shi-Joon Yoo; Luc Mertens; Mark Friedberg; Bahiyah Al Nafisi; Lars Grosse-Wortmann
Journal:  Pediatr Cardiol       Date:  2016-03-09       Impact factor: 1.655

5.  Myocardial early systolic lengthening predicts mid-term outcomes in patients with hypertrophic cardiomyopathy.

Authors:  Ozkan Candan; Cetin Gecmen; Muzaffer Kahyaoğlu; Zeki Şimsek; Mehmet Çelik; Cevat Kirma
Journal:  Int J Cardiovasc Imaging       Date:  2021-11-30       Impact factor: 2.357

6.  FHL2 expression and variants in hypertrophic cardiomyopathy.

Authors:  Felix W Friedrich; Silke Reischmann; Aileen Schwalm; Andreas Unger; Deepak Ramanujam; Julia Münch; Oliver J Müller; Christian Hengstenberg; Enrique Galve; Philippe Charron; Wolfgang A Linke; Stefan Engelhardt; Monica Patten; Pascale Richard; Jolanda van der Velden; Thomas Eschenhagen; Richard Isnard; Lucie Carrier
Journal:  Basic Res Cardiol       Date:  2014-10-31       Impact factor: 17.165

Review 7.  Critical Evaluation of Current Hypotheses for the Pathogenesis of Hypertrophic Cardiomyopathy.

Authors:  Marko Ušaj; Luisa Moretto; Alf Månsson
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

8.  Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy.

Authors:  Gabriella Captur; Luis R Lopes; Timothy J Mohun; Vimal Patel; Chunming Li; Paul Bassett; Gherardo Finocchiaro; Vanessa M Ferreira; Maite Tome Esteban; Vivek Muthurangu; Mark V Sherrid; Sharlene M Day; Charles E Canter; William J McKenna; Christine E Seidman; David A Bluemke; Perry M Elliott; Carolyn Y Ho; James C Moon
Journal:  Circ Cardiovasc Imaging       Date:  2014-09-16       Impact factor: 7.792

9.  The systolic paradox in hypertrophic cardiomyopathy.

Authors:  Trine F Haland; Nina E Hasselberg; Vibeke Marie Almaas; Lars A Dejgaard; Jørg Saberniak; Ida S Leren; Knut Erik Berge; Kristina H Haugaa; Thor Edvardsen
Journal:  Open Heart       Date:  2017-05-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.